FindTrial
Sign In

Effect of replacing the standard intravenous drug solvent from normal saline to 5% glucose solution on the incidence of hypernatremia in a COVID ICU: A before-and-after study

Effect of replacing the standard intravenous drug solvent from normal saline to 5% glucose solution on the incidence of hypernatremia in a COVID ICU: A before-and-after study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00031877
Enrollment
200
Registered
2023-05-15
Start date
2023-01-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E87.0

Interventions

Group 1: Normal saline as the standard drug solvent for intravenous drugs Group 2: Glucose 5% as the standard drug solvent for intravenous drugs

Sponsors

Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Nephrology and Medical Intensive Care
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: ICU admission COVID-19 as the main diagnosis during ICU treatment

Exclusion criteria

Exclusion criteria: Study ICU not the first admitting ICU at the Charité - Universitätsmedizin Berlin.

Design outcomes

Primary

MeasureTime frame
Plasma sodium level—

Secondary

MeasureTime frame
Incidence of hypernatremia—

Countries

Germany

Contacts

Public ContactJan-Hendrik B. Hardenberg

Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Nephrology and Medical Intensive Care,

Jan.hardenberg@charite.de+49030450614389

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 5, 2026